Jazz Pharmaceuticals (JAZZ) Earnings Date & Reports

Key Takeaways

• Jazz Pharmaceuticals is scheduled to report second quarter 2026 results on Monday, August 3, after the U.S. market close.
• Analysts' consensus estimates project non-GAAP (adjusted) earnings per share of approximately $6.18 on revenue of roughly $1.11 billion, representing a sharp rebound from the year-ago quarter.
• Investor attention is squarely on the upcoming August 25 PDUFA date (FDA action deadline) for Ziihera in first-line gastroesophageal adenocarcinoma (GEA), which could reshape the company's oncology growth trajectory.
• Commercial momentum from Xywav, Epidiolex, Zepzelca, and Modeyso will be scrutinized for sustainability amid anticipated second-half competitive headwinds in the sleep franchise.
• The company enters the report with strong stock momentum, having gained roughly 117% over the past twelve months and trading near all-time highs.
• Management's commentary on the full-year 2026 revenue guidance of $4.25 billion to $4.50 billion will be a critical signal for investors.

Earnings Context and Why It Matters

Jazz Pharmaceuticals enters its second quarter 2026 report at a pivotal moment. The Dublin-based biopharmaceutical company has transformed from a sleep-medicine specialist into a diversified rare-disease leader with a growing oncology footprint. Its first quarter delivered record revenue of $1.07 billion, a 19% year-over-year increase, and non-GAAP EPS of $6.34 — beating consensus estimates decisively. Since then, shares have rallied sharply, gaining roughly 25% since early May. The Q2 print lands just three weeks before the August 25 PDUFA date for Ziihera (zanidatamab) in first-line HER2-positive GEA, a potential blockbuster indication. Against this backdrop, the earnings report carries outsized implications not only for near-term financial validation but also for confidence in the company's broader pipeline narrative.

Earnings Expectations

Wall Street has set the bar at approximately $6.18 in non-GAAP EPS and $1.11 billion in total revenue for the second quarter, according to consensus data compiled from multiple sources. This compares to a non-GAAP loss of $8.25 per share in Q2 2025, a quarter that was heavily impacted by one-time charges. Revenue is expected to rise roughly 5.7% from the $1.05 billion reported in the same period last year.

Among individual products, analysts will be focused on several key metrics. Xywav, the low-sodium oxybate therapy for narcolepsy and idiopathic hypersomnia, generated $408 million in Q1 with 425 net patient adds, and investors will want to see whether demand momentum continued into the seasonally stronger second quarter. Epidiolex, the cannabidiol-based epilepsy treatment, posted $250 million in Q1 with 16% volume growth; sustained double-digit expansion in the adult and long-term care segments remains a key watchpoint. In oncology, Modeyso — launched in August 2025 for H3 K27M-mutant diffuse midline glioma — generated $41 million in Q1 and its ramp-up trajectory will be a central focus. Zepzelca, which delivered $101 million in Q1 following its first-line maintenance approval, is also under the microscope as management has guided for declining second-line use through the year.

Jazz has a track record of exceeding consensus estimates: the company beat expectations by roughly 36% in Q1 2026 and by approximately 26% in Q4 2025. The Earnings Whisper figure sits above the consensus at $7.00, suggesting some investors anticipate another upside surprise.

AI Screener

For investors seeking to identify trading and investment opportunities ahead of events like Jazz Pharmaceuticals' earnings, Tickeron's AI Screener offers a data-driven solution. This AI-powered stock and ETF (exchange-traded fund) discovery tool enables users to scan thousands of securities using customizable filters that span technical patterns, fundamental metrics, volatility profiles, and proprietary AI-driven signals. Whether screening by industry, market capitalization, price patterns, or performance indicators, the screener helps traders surface breakout candidates, trending stocks, and actionable market opportunities with greater speed and precision than manual research. Explore the AI Screener to refine your market analysis with intelligent, automated filtering.

Market Reaction and Investor Sentiment

Sentiment heading into the Q2 report is broadly constructive but calibrated. Jazz shares closed at $252.86 on July 31, hovering just below the 52-week high of $261.30 set days earlier. The stock has surged approximately 117% over the past twelve months and roughly 49% year-to-date, reflecting optimism around the oncology pipeline, particularly the approaching Ziihera GEA catalyst. Of the 20 analysts covering the stock, 17 rate it a Buy or equivalent, with an average price target near $267 — implying roughly 6% upside from current levels.

Still, risk factors linger. Management has cautioned that the second half of 2026 could bring increased competition in the oxybate sleep franchise from high-sodium generics and potential new wake-promoting agents entering the narcolepsy market. Declining XYREM and authorized generic revenues, alongside softening second-line Zepzelca use, are known headwinds that could temper the growth narrative. Additionally, with the stock up sharply, even a modest top-and-bottom-line beat may already be priced in. Post-earnings stock movement will likely hinge on the tone of forward-looking commentary — particularly any updates to full-year guidance or the Ziihera launch outlook.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, the earnings call will serve as a critical platform for management to frame expectations for the remainder of 2026. The most consequential near-term catalyst is the August 25 PDUFA date for Ziihera's supplemental Biologics License Application (sBLA) in first-line HER2-positive GEA. With a median overall survival of 26.4 months demonstrated in the HERIZON-GEA-01 trial — representing a meaningful improvement over the historical standard of care — approval is widely anticipated. Investors will listen closely for any FDA (U.S. Food and Drug Administration) review updates and commercial launch readiness details, including payer discussions and the potential for National Comprehensive Cancer Network (NCCN) guideline inclusion.

Another major pipeline milestone is the second interim overall survival analysis for the zanidatamab doublet arm of the HERIZON-GEA-01 trial, expected by mid-2026. Positive data could further solidify Jazz's competitive positioning in HER2-positive cancers. Later in the year or early 2027, the ACTION trial readout for Modeyso in the frontline setting post-radiation could meaningfully expand the addressable patient population for that therapy.

On the commercial front, Xywav's resilience in the face of growing generic competition will be a recurring theme. While the product has continued to add patients — approximately 300 net adds per quarter in idiopathic hypersomnia alone — payers may increasingly deploy utilization management tools as lower-cost alternatives gain volume. Epidiolex's long-term growth runway, supported by geographic expansion including the recently announced partnership with Nippon Zoki for Japan, remains an underappreciated asset. Finally, with $2.9 billion in cash and investments and robust operating cash flow, Jazz retains ample capacity for business development, and management has signaled that deal activity is a priority for 2026. Any indication of M&A (mergers and acquisitions) progress on the call could shape the investment narrative for months to come.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations